The Saudi delegation received a warm welcome at the BGI Center

On November 5th, a delegation from the National Unified Procurement Company (NUPCO) of Saudi Arabia visited BGI Genomics. The delegation was welcomed by Yin Ye, CEO of BGI Group, Zhao Lijian, CEO of BGI Genomics, and Li Ning, Deputy General Manager of BGI Genomics.

This visit marks a significant milestone in the ongoing collaboration between the two organizations. Moving forward, both parties aim to deepen their partnership, exploring opportunities in areas such as genetic testing, laboratory expansion, and the transportation of medical samples, all with the goal of advancing life sciences together.

NUPCO, fully owned by the Saudi Public Investment Fund (PIF), is the Kingdom of Saudi Arabia's procurement and supply chain management company for medical equipment and pharmaceuticals. The Saudi Public Investment Fund (PIF) is one of the largest sovereign wealth funds in the world, managing assets exceeding US$930 billion.

During the visit, NUPCO’s CEO Fahad Al Shebel, CSCO Fahad Al Buthi, and CSO Rashed Al Jlajil were introduced to BGI Genomics' pioneering technologies and innovations in proactive disease prevention and control, multi-omics research, and smart laboratories. The delegation expressed their recognition and appreciation for the company's advancements.

During the visit, both sides reviewed the cooperation history since the COVID-19 outbreak, praised the strategic partnership, engaged in in-depth exchanges on future collaboration, and reached several consensus agreements. The two parties agreed to further strengthen cooperation to enhance the capacity of localized genetic testing services in Saudi Arabia, support its public health and precision medicine efforts, and make greater contributions to public health in the country.

This visit marks an essential milestone in BGI Genomics’ and Saudi NUPCO's joint efforts to promote the global development of life sciences and improve public health. Looking ahead, the two organizations plan to pursue a broader vision and implement a far-reaching strategy, working together to tackle global health challenges. It will focus on driving sustainable development in genetic technology and healthcare, while contributing to the shared vision of better health globally.

About BGI Genomics

BGI Genomics, headquartered in Shenzhen, China, is the world's leading integrated solutions provider of precision medicine. Its services cover more than 100 countries and regions, involving more than 2,300 medical institutions worldwide. In July 2017, as a subsidiary of BGI Group, BGI Genomics (300676.SZ) officially began trading on the Shenzhen Stock Exchange.